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glands were independently associated with Xer6m, with a 
correlation coefficient of 0.454 between the model 
predictions and Xer6m. No multivariable model with multiple 
significant independent predictors was found for Xer12wk. 
A significant correlation between Xer6m and Xer12wk was found 
with a correlation coefficient of 0.627 
Conclusions: The volume and density of the parotid glands 
and the density of the submandibular glands are associated 
with xerostomia after radiotherapy. The changes of these CT 
image features over the course of treatment are more 
strongly related to xerostomia than the instantaneous feature 
values at baseline. Moreover, the feature changes in the first 
12 weeks after start of treatment are equally or even more 
strongly related to xerostomia at 6 month than at 12 weeks. 
These associations suggest that, even early after treatment, 
the CT image feature changes may be used as objective 
biomarkers of the development of xerostomia. 
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Purpose/Objective: Hematologic toxicity (HT) is an 
important side-effect of whole pelvis intensity-modulated 
radiotherapy (WP-IMRT), but association between radiation 
dose and HT remains unclear when concurrent chemotherapy 
is not prescribed. The aim of this study was to identify 
clinical and dosimetric predictors of HT in a cohort of chemo-
naÏf patients treated with WPRT. 
Materials and Methods: The first 121 patients enrolled in a 
prospective observational study, treated with adjuvant 
(n=72) or salvage (n=49) WP-IMRT in a single Institute were 
available (static field IMRT: 19; VMAT/Rapidarc:57; Helical 
Tomotherapy:45). Pelvic bones, used as a surrogate for pelvic 
bone marrow (BM), were contoured according to Mell et al 
[IJROBP 2006] and divided in four subvolumes: ilium (IL), 
lumbosacral spine (LS), lower pelvis (LP) and whole pelvis 
(WP). The volume of each BM region receiving 3, 5, 10, 20, 
30, 40 and 50 Gy (V3-50) was recovered. 
Absolute values of lymphocytes (ALC), white blood cell (WBC) 
and neutrophils (N) were prospectively collected before 
WPRT, at half WPRT, at end WPRT, at 3m and at 12 months 
after WPRT. HT was graded according to CTCAE v. 3.0: Grade 
3 (G3) and Grade 1 (G1) events were considered as end-
points for acute (nadir value) and late HT respectively. Uni- 
and backward multi-variable logistic regression was 
performed to assess correlation between clinical/DVH 
parameters and HT. A previously introduced method based on 
DVH differences between patients with/without HT was used 
to select the most discriminative DVH parameters.  
Results: The nadir of WBC and N (median values= 65% and 
74% of baseline respectively) was found at half-therapy while 
it was at the end of RT for ALC (median= 30% of baseline). 
No patients showed acute G3 neither late G1 WBC and N 
toxicities. Interestingly, the mean value of ALC at 1 year was 
54% of baseline: 28 acute G3 and 14 late G1 lymphopenias 
were found. Then, the analysis was restricted to ALC at the 
end of therapy (ALCend) and at 12 months (ALC12m). 
At univariate analysis, a lower baseline ALC (ALCbase) was 
correlated with G3 ALCend and G1 ALC12m (p=0.003 and 
p<0.001, respectively). Concerning dosimetric parameters, 
IL-V30/IL-V40 and WP-V40 were correlated with acute G3 
ALCend and late G1 ALC12m (p=0.003). The resulting model 
for ALCend included ALCbase and WP-V40 (AUC =0.73); the 
model for ALC12m included ALCbase and IL-V40 (AUC= 0.82). 
Best cut-off values (assessed by ROC) discriminating patients 
with/without lymphopenia were: ALCbase ≤1830 x 10(9)/L 
and WP-V40 >599.4 cc (G3 ALCend); ALCbase ≤1780 x 10(9)/L 




Conclusions: Two-variable models including ALCbase and 
DVH parameters of pelvic BM may predict acute G3 and late 
G1 lymphopenia after WP-IMRT in post-prostatectomy RT. 
The model could be used to reduce HT by constraining BM. 
Further validation on a larger population is ongoing.  
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Purpose/Objective: A final accuracy of positioning < 2 mm is 
the recommended tolerance level for image-guided 
radiotherapy (IGRT) for spine stereotactic radiosurgery (SRS) 
in RTOG 0631. However, the tolerance level for rotation is 
not specified. This study investigated experimentally the 
effect of rotational setup errors on dose distribution for spine 
SRS. 
Materials and Methods: The contour definitions and 
treatment planning were as per RTOG 0631. A 16-Gy dose was 
prescribed in a single fraction by step-and-shoot intensity-
modulated radiation therapy (IMRT) using seven coplanar 
beams with the Vero4DRT (Mitsubishi Heavy Industries, Ltd., 
Hiroshima, Japan, and Brainlab AG, Feldkirchen, Germany). 
An isocenter was placed inside the vertebral body. Setup 
error patterns were categorized into three groups. Only 
translational errors were generated for Group A, with the 
translational errors measuring +1, +2, +3, and +5 mm in the 
lateral (LAT), longitudinal (LNG), and vertical (VRT) 
directions, respectively. Only rotational errors were 
generated for Group B, and measured +1°, +2°, +3°, and +5° 
in terms of the tilt or roll angle. Combinations of 
translational and rotational errors occurred in Group C. 
Translational errors of 0 to 2 mm were generated in each 
direction and rotational errors of ±1° or ±2° in each 
direction. Data were acquired with a Delta4 phantom 
(ScandiDos, Uppsala, Sweden) and setup errors were 
generated with HexaMotion (ScandiDos, Uppsala, Sweden). 
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All measured values were evaluated using the gamma index 
with dose difference/distance-to-agreement criteria of 3%/2 
mm (γ3%/2 mm) for the area receiving more than 10% isodose as 
compared with a static pattern. A γ passing rate > 90% was 
considered acceptable in this study. 
Results: For Group A, γ3%/2 mm was less than 90% for 
translational errors ≥ 3 mm in the LAT and VRT directions and 
≥ 2 mm in the LNG direction. For Group B, γ3%/2 mm was less 
than 90% for rotational errors ≥ 3° (Table 1). Table 2 
summarizes γ3%/2 mm for Group C. Translational errors of 2 mm 
and rotational errors of 2° always gave a γ3%/2 mm of less than 
90%. γ3%/2 mm was less than 90% for tilt and roll angles of 2°, 
even without translational errors. Even when translational 
errors were 1 mm, γ3%/2 mm was less than 90% for two patterns 
with rotational errors of 1°. By correcting the translational 
errors, γ3%/2 mm was more than 90% for tilt and roll angles of 
1°. Note that correction of the translational errors degraded 
γ3%/2 mm for the pattern with a tilt angle of 1° and roll angle of 
-1° and with a tile angle of 2° and roll angle of -2°. 
 
Conclusions: This study have demonstrated that rotational 
errors ≥ 3° in either angle or ≥ 1° in multiple angles most 
likely gave a γ3%/2 mm of less than 90%, even with translational 
errors < 2 mm; therefore, it is preferable to correct 
rotational errors < 2° in each angle for spine SRS under 
correction of translational errors.  
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HPV-status has been recognized as the strongest prognostic 
indicator for treatment outcome of oropharynx cancer 
overpowering clinical and other biological tumor 
characteristics. Nevertheless, the latter remain of value for 
selection of subgroups within the HPV-negative and HPV-
positive entities that qualify for treatment intensification or 
de-intensification, respectively. Among the clinical factors 
are smoking habits and T- and N-stage. Classical radio- and 
chemotherapy resistance mechanisms include DNA-repair 
capacity, tumor repopulation and hypoxia, for which various 
biomarkers have been identified. To improve the outcome of 
HPV-negative patients the challenge is to identify the pivotal 
resistance mechanisms and apposite treatments to 
counteract them. There will not be a “one-size-fits-all” 
solution and customized treatment additions and/or 
adaptations will be essential, necessitating selection tools. 
For a biomarker assay to be successful for wide clinical 
application it should preferably be non-invasive, fast, not too 
complex, and suited for repetitive assessments. PET-scanning 
meets these criteria although specific tracer availability can 
be a limitation. The current status and future directions of 
PET-scanning with proliferation- and hypoxia-specific tracers 
for outcome prediction and early response assessment will be 
discussed. 
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HPV negative head and neck cancer remains a challenging 
disease with a poor prognosis for many patients, especially 
those with locally advanced disease stage. 
Future developments are likely to focus on a number of 
areas. 
Techniques to identify and target patients with radioresistant 
disease are required. Current clinical trials in this area are 
testing radiation dose escalation to overcome 
radioresistance. Advances in functional imaging have allowed 
the detection of sub-volumes of radioresistant tumour tissue 
due to hypoxia, proliferation or other processes. Dose 
painting techniques are in development to attempt to deliver 
increased radiatin dose to these areas. 
In parallel the development of combinations of radiation with 
chemotherapy and novel agents are underway. The ability of 
agents to overcome the processes leading to radioresistance 
such as hypoxia, DNA damage repair and other processes will 
be discussed.  
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Purpose/Objective: In head and neck squamous cell 
carcinoma (HNSCC), the overall treatment time of radiation 
(OTT) is significantly associated with locoregional control 
(LRC), which is consistent with rapid repopulation of cancer 
clonogens during radiotherapy. However, the importance of 
